Roman F

Roman Fleck, PhD, MBA

Co-Founder & Chief Executive Officer

Janpix

Roman Fleck, PhD, MBA, is the Co-Founder and Chief Executive Officer of Janpix and a Venture Advisor to Medicxi (formerly Index Ventures).

Previously, Roman was a Principal at Index Ventures where, among others, he invested in and represented Index Ventures on the boards of GlycoVaxyn (acquired by GSK), Versartis, and Novocure (NASDAQ: NVCR). Earlier at Index Ventures he was involved with Funxional Therapeutics (acquired by Boehringer Ingelheim International GmbH) and Micromet (acquired by Amgen).

Roman started his career at Boehringer Ingelheim in Connecticut, USA where he led drug development projects in oncology, inflammation and cardiovascular disease, advancing several compounds from pre-clinical to clinical stage.

Roman received a PhD in Bio-Organic Chemistry from M.I.T. as well as an MBA from NYU’s Stern School of Business.

Read more here about Janpix

Your browser is out-of-date!

Update your browser to view this website correctly. Outdated Browser

×